HOXA10 and ovarian carcinoma: Recently, a clinical trial found that low-dose gemcitabine induces hypomethylation of CpG islands within the HOXA10 and HOXA11 genes, restoring sensitivity to carboplatin and improving the survival rate in patients diagnosed with ovarian cancer [52].